stockrow
Saturday 7 November 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −54.3%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
7.30
0.54
+7.99%
Follow OLMA
Alert me
Olema Pharmaceuticals, Inc. (OLMA) P/E ratio
Olema Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| GERN Geron Corporation compare | n/m |
| APMD Apnimed, Inc. compare | 0.8× |
| OBX Obsidian Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)